Peptide Therapy

Peptide Bioregulators

14 articles on Peptide Bioregulators by Dr. med. univ. Julian Douwes: Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows; and more.

14 articles · 87 min total
01

Bronchogen (AEDL): Lung Bioregulator, Rat Data Only

Bronchogen is the Khavinson tetrapeptide Ala-Glu-Asp-Leu marketed for the bronchi. Evidence is rat COPD models and cell work from one group; no human trials.

Bronchogen (AEDL): Lung Bioregulator, Rat Data Only
02

Cardiogen (AEDR): The Heart Bioregulator's Thin Evidence

Cardiogen (Ala-Glu-Asp-Arg) is a Khavinson tetrapeptide sold for the heart. Data are cell cultures and rat tumour studies from one group; no human trials.

Cardiogen (AEDR): The Heart Bioregulator's Thin Evidence
03

Cartalax (AED): Cartilage Bioregulator, Cell Data Only

Cartalax (Ala-Glu-Asp) is a Khavinson Cytogen marketed for cartilage and joints. Evidence is human cell cultures and rat kidney work; no osteoarthritis trials.

Cartalax (AED): Cartilage Bioregulator, Cell Data Only
04

Cortagen (AEDP): Brain Bioregulator and Nerve-Repair Data

Cortagen (Ala-Glu-Asp-Pro) is a Khavinson brain-cortex tetrapeptide. Rat nerve-regeneration and ischaemia data exist; human evidence is an unpublished claim.

Cortagen (AEDP): Brain Bioregulator and Nerve-Repair Data
05

Crystagen (EDP): Immune Bioregulator With Almost No Data

Crystagen (Glu-Asp-Pro) is a Khavinson Cytogen sold for the immune system. PubMed holds a few cell and docking studies, no human trials. What is known.

Crystagen (EDP): Immune Bioregulator With Almost No Data
06

Livagen (KEDA): Liver Bioregulator and Chromatin Studies

Livagen (Lys-Glu-Asp-Ala) is a Khavinson liver tetrapeptide. Data are test-tube chromatin studies in elderly lymphocytes and rat work; no human trials.

Livagen (KEDA): Liver Bioregulator and Chromatin Studies
07

Ovagen (EDL): Sold for the Liver, Studied in the Kidney

Ovagen (Glu-Asp-Leu) is a Khavinson Cytogen sold for liver and gut. Its PubMed studies are rat kidney and cell work. Not an ovary peptide. What the data show.

Ovagen (EDL): Sold for the Liver, Studied in the Kidney
08

Pinealon (EDR): Brain Bioregulator, Evidence and Dosing

Pinealon (Glu-Asp-Arg) is a Khavinson tripeptide sold for the brain. Cell and mouse data plus one small uncontrolled human study. Evidence, dosing and reports.

Pinealon (EDR): Brain Bioregulator, Evidence and Dosing
09

Prostamax (KEDP): Prostate Bioregulator, What Is Known

Prostamax (Lys-Glu-Asp-Pro) is a Khavinson tetrapeptide sold for the prostate. Data are lymphocyte chromatin and rat tissue studies; no BPH or PSA trials.

Prostamax (KEDP): Prostate Bioregulator, What Is Known
10

Testagen (KEDG): Sold for the Testes, Studied in Chickens

Testagen (Lys-Glu-Asp-Gly) is sold as a testicular bioregulator, but its PubMed studies describe a pituitary-derived peptide tested in chickens. The evidence.

Testagen (KEDG): Sold for the Testes, Studied in Chickens
11

Thymogen (Glu-Trp): Russian Drug, Failed Western Trial

Thymogen (Glu-Trp, oglufanide) is a licensed immunostimulant in Russia. The same dipeptide failed a US phase III trial in Kaposi sarcoma. Evidence and doses.

Thymogen (Glu-Trp): Russian Drug, Failed Western Trial
12

Vesugen (KED): Vascular Bioregulator, Evidence and Dosing

Vesugen (Lys-Glu-Asp) is a Khavinson Cytogen sold for blood vessels. Endothelial cell data, Alzheimer mouse work and one small human study. What it shows.

Vesugen (KED): Vascular Bioregulator, Evidence and Dosing
13

Vilon (Lys-Glu): Thymus Dipeptide, Mouse Lifespan Data

Vilon (Lys-Glu) is a Khavinson thymus dipeptide. Mouse lifespan and tumour studies, cell data and one small diabetes study exist; no controlled human trials.

Vilon (Lys-Glu): Thymus Dipeptide, Mouse Lifespan Data
14

Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows

Dr. med. univ. Julian Douwes reviews Russian short-chain peptide bioregulators — Thymalin, Pinealon, Cortagen, Ventfort — and the Khavinson protocol's evidence for longevity.

Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows
← Back to Peptide Therapy